<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> in skeletal muscle is a major risk factor for the development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in women with <z:hpo ids='HP_0000147'>polycystic ovary</z:hpo> syndrome (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCOS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>In patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in skeletal muscle is associated with abnormalities in insulin signaling, fatty acid metabolism, and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> oxidative phosphorylation (OXPHOS) </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCOS</z:e> patients, the molecular mechanisms of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> are, however, less well characterized </plain></SENT>
<SENT sid="3" pm="."><plain>To identify biological pathways of importance for the pathogenesis of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCOS</z:e>, we compared gene expression in skeletal muscle of metabolically characterized <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCOS</z:e> patients (n = 16) and healthy control subjects (n = 13) using two different approaches for global pathway analysis: gene set enrichment analysis (GSEA 1.0) and gene map annotator and pathway profiler (GenMAPP 2.0) </plain></SENT>
<SENT sid="4" pm="."><plain>We demonstrate that impaired insulin-stimulated total, oxidative and nonoxidative <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCOS</z:e> patients are associated with a consistent downregulation of OXPHOS gene expression using GSEA and GenMAPP analysis </plain></SENT>
<SENT sid="5" pm="."><plain>Quantitative real-time PCR analysis validated these findings and showed that reduced levels of peroxisome proliferator-activated receptor gamma coactivator alpha (<z:chebi fb="6" ids="26336">PGC</z:chebi>-1alpha) could play a role in the downregulation of OXPHOS genes in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCOS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In these women with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCOS</z:e>, the decrease in OXPHOS gene expression in skeletal muscle cannot be ascribed to <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>This supports the hypothesis of an early association between <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and impaired <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> oxidative metabolism, which is, in part, mediated by reduced <z:chebi fb="6" ids="26336">PGC</z:chebi>-1alpha levels </plain></SENT>
<SENT sid="8" pm="."><plain>These abnormalities may contribute to the increased risk of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> observed in women with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCOS</z:e> </plain></SENT>
</text></document>